Horizon Pharma receives additional U.S. patent allowance for Duexis Horizon Pharma announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application Serial No. 13/620,150 entitled "Stable Compositions of Famotidine and Ibuprofen" with claims that cover Duexis tablets. Duexis is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers.
Hyperion Therapeutics downgraded to Hold from Buy at Brean Capital Brean Capital downgraded Hyperion Therapeutics (HPTX) citing the takeover by Horizon Pharma (HZNP). Brean views the buyout price as "reasonable and fair."